2nd Quarter - Report

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$780,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S.2543 - Prescription Drug Pricing Reduction Act of 2019 HR 1499: Protecting Consumer Access to Generic Drugs Act Cell, gene and radioligand therapies 340B Drug Discount Program Drug Importation Outcomes based Contracting/Value based arrangements Orphan Drugs Medicaid Payment Reform AMP Cap S 1895 - Lower Health Care Costs Act HR 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R.478 - Safe and Affordable Drugs from Canada Act of 2019 H.R.2011 - Protecting Access to Biosimilars Act of 2019 H.R.2296 - FAIR Drug Pricing Act of 2019 S.61 - Safe and Affordable Drugs from Canada Act of 2019 S.1140 - Protecting Access to Biosimilars Act of 2019 S.1384 - Prescription Drug Rebate Reform Act of 2019 S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 S.1227 - Prescription Pricing for the People Act of 2019 H.R.447 - Affordable and Safe Prescription Drug Importation Act H.R.1922 - Restoring Access to Medication Act of 2019 H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes H.R.5304 - PBM Transparency in Prescription Drug Costs Act S.97 - Affordable and Safe Prescription Drug Importation Act S.657 - A bill to amend title XXVII of the Public Health Service Act to establish requirements with respect to prescription drug benefits Transparency policy issues Drug cost and pricing policy issues PDUFA, BSUFA, GDUFA Drug vial size policy issues Pharmaceutical supply chain HR 6800, Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act) H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act of 2020 S. 3538, Strengthening Americas Supply Chain and Medical Security Act H.R. 6431, Made in America Emergency Preparedness Act HR 6080, Prevent Drug Shortages Act S. 3432, Securing Americas Medicine Cabinet Act of 2020 H.R. 6670, Prescription for American Drug Independence Act of 2020 H.R. 6930, MADE in America Act HR 4439, Creating Hope Reauthorization Act Pharmaceutical quality COVID 19 H.R 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201 - Families First Coronavirus Response Act H.R. 748 and S. 3548 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act) H.R. 3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 S. 3370: Coronavirus Vaccine Act S. 3548: CARES Act H.R. 6080: Preventing Drug Shortages Act Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients Drug shortages policy issues Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45) Diversity in Clinical Trials FY 2021 Labor-HHS Appropriations Cures 2.0 Energy and Commerce RFI Part B Home Infusion Notice of Benefit Payment Parameters (NBPP) Priority Review Voucher (PRV) H.R. 4400, The Advancing Education on Biosimilars Act of 2019 Vaccines

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
COURTNEY LEE-ASHLEY New —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SEEMIN PASHA New —
COURTNEY PIRON New —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Food & Drug Administration (FDA); State, Dept of (DOS); Office of Management & Budget (OMB); White House Office; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); U.S. Agency for International Development (USAID); SENATE

Bills named: H.R. 4439 (116th), H.R. 6201 (116th), H.R. 3772 (116th), H.R. 4710 (116th), S. 3538 (116th), H.R. 447 (116th), S. 2543 (116th), S. 1391 (116th), H.R. 2296 (116th), H.R. 2011 (116th), S. 61 (116th), H.R. 748 (116th), H.R. 6670 (116th), S. 3635 (116th), S. 657 (116th), H.R. 478 (116th), H.R. 6074 (116th), H.R. 6080 (116th), S. 3370 (116th), S. 1140 (116th), H.R. 987 (116th), S. 3432 (116th), H.R. 6800 (116th), H.R. 1922 (116th), H.R. 6930 (116th), H.R. 6431 (116th), S. 1227 (116th), H.R. 1499 (116th), H.R. 4400 (116th), H.R. 5304 (116th), S. 97 (116th), H.R. 2064 (116th), S. 1384 (116th), S. 3548 (116th)

Copyright/Patent/Trademark CPT

Biopharmaceutical Intellectual Property Data exclusivity Patent Litigation Reform and Issues Related to Post Grant Proceedings at PTO BPCIA Patents Inter Partes Review at PTO Biosimilars S 1416 - Affordable Prescriptions for Patients Act of 2019 H.R.465 - Prescription Drug Price Relief Act of 2019 H.R.938 - BLOCKING Act of 2019 H.R.987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R.1046 - Medicare Negotiation and Competitive Licensing Act of 2019 Bayh-Dole Act Section 101 H.R.3991 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 H.R.4398 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 S.1617 - Second Look at Drug Patents Act of 2019 HR 4712 - Fairness in Orphan Drug Exclusivity Act H.R. 4850: Biologic Patent Transparency Act - Provisions related to prescription drug patent disclosures H.R. 5133: Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 - Provisions related to prescription drug exclusivity periods and manufacturer behavior Intellectual Property Issues in Response to coronavirus S. 2387, We Protect American Investment in Drugs Act of 2019 S. 64, Preserve Access to Affordable Generics & Biosimilars Act of 2019

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH New —
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY New —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SEEMIN PASHA New —
COURTNEY PIRON New —

Contacted: Food & Drug Administration (FDA); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); White House Office; Health & Human Services, Dept of (HHS); State, Dept of (DOS); SENATE

Bills named: H.R. 465 (116th), H.R. 4850 (116th), H.R. 5133 (116th), S. 2387 (116th), H.R. 938 (116th), H.R. 4712 (116th), H.R. 3991 (116th), H.R. 1046 (116th), H.R. 4398 (116th), S. 1617 (116th), H.R. 987 (116th), S. 64 (116th)

Foreign Relations FOR

Foreign Investment Risk Review Modernization Act of 2017 (FIRMMA) CFIUS Reform Foreign Agents Registration Act (FARA) Reform S.1762 - Foreign Agents Disclosure and Registration Enhancement Act of 2019

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
COURTNEY PIRON New —

Contacted: State, Dept of (DOS); Commerce, Dept of (DOC); U.S. Agency for International Development (USAID); Centers For Medicare and Medicaid Services (CMS); White House Office; SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Office of Management & Budget (OMB)

Bills named: S. 1762 (116th)

Trade (domestic/foreign) TRD

Free Trade Agreements - Intellectual Property and Transparency Provisions - Free Trade Agreements Access to Medicines Issues Global Health Issues India, China and Canada IP and Market Access Issues Sub-standards Medicines Quality of Medicines International Market Access and Intellectual Property Issues Biopharmaceutical Innovation Policies Regulatory Cooperation USTR Special 301 Report/National Trade Estimate Trade Policy Tariffs CFIUS USMCA US Swiss Trade Agreement Pharmaceutical supply chain

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
COURTNEY PIRON New —

Contacted: U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); U.S. Agency for International Development (USAID); State, Dept of (DOS); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); White House Office; Office of Management & Budget (OMB)

Taxation/Internal Revenue Code TAX

OECD Digital Tax ACA Pharmaceutical Industry Fee Exclusions Orphan Drug Tax Mobile Workforce Thin Capitalization Rules 163(j) Base Erosion Anti-Abuse Tax (BEAT) Tax Cuts & Jobs Act Implementation Innovation Box Treasury Proposed BEAT Regulations Tax Treaties Coronavirus Aid, Relief, and Economic Security Act (CARES Act) (HR 748)(S. 3548) Pharmaceutical supply chain incentives

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
COURTNEY PIRON —

Contacted: U.S. Trade Representative (USTR); SENATE; Office of Management & Budget (OMB); State, Dept of (DOS); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); White House Office; Food & Drug Administration (FDA); U.S. Agency for International Development (USAID); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 748 (116th), S. 3548 (116th)

Medicare/Medicaid MMM

Medicare Part A, B and D AMP Cap H.R 3 S.2543 - Prescription Drug Pricing Reduction Act of 2019 H.R. 1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019 Innovative pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics Drug Pricing Outcomes Based Contracts/value based arrangements Medicaid H.R.275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R.448 - Medicare Drug Price Negotiation Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.107 - To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R.4455 - BIOSIM Act H.R.4619 - Pharmaceutical Rebates for Excessive Pricing Above Inflation Act HR. 3772, the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 HR. 4597 - Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 S.3466 - ACCESS for Biosimilars Act of 2020 HR. 6179 - Increasing Access to Biosimilars Act of 2020 HR. 4629 - Star Rating for Biosimilars Act S. 3129: Lower Costs, More Cures Act of 2019 S. 3384: Lowering Prescription Drug Prices for America's Seniors and Families Act of 2020 S. 3457: Preserving Patient Access to Home Infusion Act - Provisions related to Medicare and prescription drug access H.R.5741 - Strengthening Innovation in Medicare and Medicaid Act Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Transparency policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues ANPRM; Medicare Program; International Pricing Index Model for Medicare Part B Drugs (CMS-5528-ANPRM) Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection (RIN 0936-AA08) Proposed Rule; Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans (CMS-9916-P) Reimbursement for cell therapy products S. 3353/H.R. 5534, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act Patient Cost-Sharing and Smoothing S. 4134, Increasing Access to Biosimilars Act of 2020 S. 102, Prescription Drug Price Relief Act of 2019

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY New —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SEEMIN PASHA New —
COURTNEY PIRON New —

Contacted: U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Food & Drug Administration (FDA); Office of Management & Budget (OMB); SENATE; State, Dept of (DOS); White House Office; Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES

Bills named: H.R. 107 (116th), H.R. 19 (116th), H.R. 6179 (116th), H.R. 4619 (116th), H.R. 4597 (116th), H.R. 3 (116th), H.R. 448 (116th), H.R. 4455 (116th), S. 3129 (116th), S. 3457 (116th), S. 102 (116th), S. 3384 (116th), H.R. 1046 (116th), H.R. 3772 (116th), H.R. 275 (116th), H.R. 5534 (116th), S. 377 (116th), S. 3353 (116th), S. 4134 (116th), S. 3466 (116th), H.R. 4629 (116th), S. 2543 (116th), H.R. 5741 (116th)

Budget/Appropriations BUD

Certified Importer Program (CIP) Biosimilars Importation Drug Pricing Value of Medicine Blocking Act Fiscal year 2021 Appropriations

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY New —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
COURTNEY PIRON New —

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; State, Dept of (DOS); Food & Drug Administration (FDA); Office of Management & Budget (OMB); U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); White House Office

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.